NEW YORK — Erasca Inc. shares rose sharply on Wednesday, climbing 8.96 percent to $12.53 in midday trading as investors continued to reward the clinical-stage oncology company for progress with its experimental pan-RAS inhibitor and broader pipeline advancements in targeted cancer therapies.

The precision oncology developer, focused on RAS/MAPK pathway-driven cancers, has seen extraordinary gains in 2026, with the stock up more than 700 percent year-to-date in some tracking periods. Wednesday’s move reflects sustained enthusiasm following positive early clinical data for its lead candidate ERAS-0015 and strategic collaborations aimed at accelerating development.

Erasca reported encouraging preliminary Phase 1 dose escalation results for ERAS-0015 in April, showing robust monotherapy responses in patients with KRAS-mutant solid tumors, particularly non-small cell lung cancer. The data demonstrated objective response rates reaching 62-75 percent in certain heavily pretreated patient groups, positioning the molecular glue as a potential best-in-class therapy in the competitive RAS-targeting space.

Positive Clinical Momentum Drives Interest

The company’s ERAS-0015 program has generated significant attention for its “home run profile” in early testing, according to analysts. The drug’s ability to inhibit multiple RAS mutations while maintaining a manageable safety profile has fueled optimism about its potential across various tumor types.

In May, Erasca announced a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015 in combination with KEYTRUDA (pembrolizumab). This partnership is expected to provide valuable insights into combination strategies, potentially expanding the drug’s utility in immunotherapy settings.

The company is scheduled to present at the Jefferies Global Healthcare Conference on June 3, where management is likely to provide further updates on its RAS franchise and upcoming milestones. Such appearances often serve as catalysts for biotech stocks with active clinical programs.

Strong Analyst Support

Wall Street has responded favorably to Erasca’s progress. Multiple firms maintain Buy ratings, with price targets ranging from $18 to $26. Analysts highlight the company’s focused approach to RAS pathway inhibition and its potential to address significant unmet needs in oncology.

The stock’s dramatic rise this year has attracted both momentum investors and longer-term biotechnology specialists. While some funds have trimmed positions after the massive run-up, others have added to holdings, citing confidence in the pipeline’s future value.

Pipeline and Strategic Focus

Erasca is advancing a portfolio of programs targeting oncogenic drivers in the RAS/MAPK pathway. Beyond ERAS-0015, the company is developing additional candidates aimed at specific mutations and resistance mechanisms that limit current treatment options.

The company’s strategy centers on precision medicine approaches that match therapies to patients with specific genetic alterations. This focus aligns with broader industry trends toward personalized cancer treatments and could support premium pricing and faster regulatory pathways if clinical data continue to impress.

Financially, Erasca maintains a solid cash position following earlier financing activities, providing runway to advance its clinical programs through key data readouts. The company reported its first-quarter 2026 results in May, detailing progress across its pipeline while managing operating expenses typical for a development-stage biotech.

Competitive Landscape in Oncology

The RAS space has become increasingly competitive, with several companies pursuing inhibitors of KRAS and related mutations. Erasca’s pan-RAS approach aims to offer broader activity than mutation-specific drugs, potentially addressing a larger patient population.

While patent disputes and safety considerations have created occasional volatility, the company has maintained that its programs are on track. Management has emphasized rigorous safety monitoring and data-driven development as it advances toward later-stage trials.

Market Reaction and Outlook

Wednesday’s trading volume was elevated as investors reacted to ongoing positive sentiment in the biotechnology sector. Small- and mid-cap oncology stocks with promising clinical assets have attracted renewed interest amid a favorable environment for innovation-driven healthcare investments.

Looking ahead, key catalysts for Erasca include additional data readouts from ERAS-0015, progress in combination cohorts, and potential regulatory interactions. Successful execution on these milestones could further validate the company’s platform and support additional upside.

Risks remain typical for clinical-stage biopharmaceutical companies, including trial delays, regulatory hurdles, and competition. However, Erasca’s singular focus on RAS-driven cancers and strong early signals have helped differentiate it within the crowded oncology field.

As the company continues to mature its pipeline, it represents a high-risk, high-reward opportunity in the precision oncology space. Investors will closely monitor upcoming presentations and data updates for further evidence of ERAS-0015’s potential and the broader platform’s viability.

The surge on Wednesday underscores the market’s appetite for companies demonstrating tangible progress toward addressing difficult-to-treat cancers. With several meaningful milestones on the horizon, Erasca is well-positioned to remain in focus as it works to translate scientific innovation into potential new treatment options for patients with RAS/MAPK pathway alterations.

Everybody is talking about $4.50 gasoline at the pump. And all the usual suspects from the lefty press, and of course the Democratic party, and even the business press that ought to know better, anyway, they’re all talking about recession.

Of course they’re against President Trump. They’re against the Iran war. And they love to crow about high energy prices destroying the Trumpian economy.

Only trouble is, not only are we not going into a recession — the economy is booming. It is picking up steam. Profits are the mothers’ milk of stocks and the lifeblood of the economy. And right now profits are soaring by 15 percent.

Here’s Mr. Trump earlier today on the subject: “So the Americans are benefiting. Working today we have the most working and we have 401k’s that their all time high, highest they’ve ever been.” 

Mr. Trump added: “And that goes along with the stock market, which is the highest it’s ever been under my most favored nation agreements. This is something that I wish the media would talk about, because to me, it’s one of the biggest things ever to happen in our country.”

Now I do feel everyone’s pain regarding gas and diesel prices, and fertilizer prices on the farm. Yet it is a small price to pay to get ride of the Gestapo in Iran. Actually, less than 5 percent of consumer spending is affected by gas prices.

Meanwhile, the Atlanta Fed is looking at a huge 4.3 percent increase in second-quarter real GDP. That is a big number.

Under the hood, consumer spending, despite gas prices, is estimated to rise by 2.9 percent annually, and business capital investment by 9.4 percent annually. Wages, which mean more to working folks’ kitchen tables than GDP, are rising above 4 percent when you include hours worked.

Output per person or productivity is up a whopping 2.9 percent over the past year. Almost 3 percent.

And unit labor costs, which is the most basic price indicator in the whole economy, wages less productivity, is up only 1.2 percent over the past year.

The AI footprint is now bigger than the dotcom boom, according to John Carney.

And yes, topline prices are up by around 4 percent, but actually core goods prices, excluding food and energy, only 1.1 percent. So the tariff-flation craze never panned out.

Actually, if it weren’t for a one off bad import number last quarter, GDP would’ve been up 3.2 percent. That’s going to reverse this quarter and will drive the economy even faster. Here’s Treasury Man Scott Bessent earlier today:

“Sir, on the economy, two words: resilience and prosperity. The continued resilience of the economy speaks for itself even during the Iran conflict.”

Meanwhile, the stock market is just booming across the board. The Dow is holding above 50,000. And all the other stock indexes are making record highs, which is a sign of confidence in the future economy.

Did you know, by the way, that in America, total household wealth, which includes mainly stocks, bonds, real estate, and cash, is about $180 trillion. Which is about six times larger than our gross domestic product, or our federal debt in public hands. $180 trillion folks. It’s remarkable.

No country is even remotely close to that number. And on a per person basis, our GDP is more than $90,000. In Communist China, it’s less than $14,000.

The Chinese stock market hasn’t moved in years. And the United States is producing more oil and gas than anyone could ever imagine. We are the biggest supplier in the world today. This is the Trumpian economy. If only somebody would write about it.  

Just think of it.

Bob Brackett
Bernstein Institutional Services LLC, Research Division

Good afternoon. We’ll be kicking off our session. Welcome again to the 42nd Annual Strategic Decisions Conference. I am Bob Brackett, Co-Head of Energy and Transition here at Bernstein. We are not expecting a fire alarm or a fire drill. And so if the alarm rings, please take it seriously.

The first path of exit is out the back door to the right, all the way to the escalators that you came up down to the street and wait for further instructions. If for whatever reason that path is blocked, you go straight back. There’s a series of internal stairwells that are well marked, take one of those down and follow the lighted path there.

Ultimately, this is your conversation. This is a fireside chat. There’s [ floor ] up on stage, but there’s more in the audience. And so ultimately, you should drive the conversation to do that, you will use either the website you’ve already pulled up, this pigeonhole.

If you need the QR code, there’s a number of blue sheets of paper around the room that you can get that from. And what we’ll do is I’ll adjourn in one second. And we’re going to follow a pyramid principle, which is we’re going to start high. We’re going to talk about the macro environment in which ONEOK operates, and then we’re going to talk strategy, and then we’re going to move down into assets and operations.

As the US and China vie for AI dominance, energy has become a crucial battleground. Their competition extends beyond technology to securing sustainable and strategic energy resources, highlighting the importance of energy resilience and innovation in shaping global power dynamics in the race for technological supremacy.

The race for renewable energy dominance between the US and China is intensifying. China currently leads globally, with substantial investments in solar, wind, and hydropower projects. Its aggressive push towards clean energy aims to reduce reliance on coal and position itself as a leader in the green economy. Meanwhile, the US has made significant strides, fueled by policy initiatives like the Inflation Reduction Act, which boosts renewables development and innovation.

Despite the US’s advanced technological edge, catching up to China remains a formidable challenge. China’s vast manufacturing capabilities, government support, and large-scale infrastructure projects give it a distinct advantage. The US faces hurdles such as political gridlock, regulatory delays, and supply chain issues, which slow progress in scaling renewable energy deployment.

However, the US has the potential to close the gap with strategic investments and technological advancements. By fostering collaborations, improving policy consistency, and accelerating deployment, the US can boost its renewable capacity. While China currently leads, sustained effort and innovation could see the US competing more closely in the renewable energy race in the future.

source

Other People are Reading